Welcome to Crene Biotechnology!

+86-576-88205808

Product :

Prostacyclin sodium salt Epoprostenol sodium

Prostacyclin sodium salt Epoprostenol sodium 61849-14-7
Size Price Stock Quantity
Get Quotation Now Add to Cart Bulk Inquiry
Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.
Chemical Information
Product name:Prostacyclin sodium salt Epoprostenol sodium Purity:98% min
CAS NO:61849-14-7 Solubility:Soluble in DMSO, not in water
Molecular Formula:C20H31NaO5 Package:Package according to customer requirements
Molecular Weight:374.45 Storage:0 - 4 C for short term (days to weeks), or -20 C for long term (months).
Quality control
Remarks

Epoprostenol Sodium is a potent vasodilator and antiplatelet substance with a very short physiologic half-life. The sodium salt is used primarily for the treatment of pulmonary hypertension. Epoprostenol sodium inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue.

References

1: Saito Y, Nakamura K, Akagi S, Sarashina T, Ejiri K, Miura A, Ogawa A, 
Matsubara H, Ito H. Epoprostenol sodium for treatment of pulmonary arterial 
hypertension. Vasc Health Risk Manag. 2015 May 14;11:265-70. doi: 
10.2147/VHRM.S50368. eCollection 2015. Review. PubMed PMID: 25999730; PubMed 
Central PMCID: PMC4437604.

2: Chin KM, Badesch DB, Robbins IM, Tapson VF, Palevsky HI, Kim NH, Kawut SM, 
Frost A, Benton WW, Lemarie JC, Bodin F, Rubin LJ, McLaughlin V. Two formulations 
of epoprostenol sodium in the treatment of pulmonary arterial hypertension: 
EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a 
phase IV, open-label, randomized study. Am Heart J. 2014 Feb;167(2):218-225.e1. 
doi: 10.1016/j.ahj.2013.08.008. Epub 2013 Oct 16. PubMed PMID: 24439983.

3: Tamura Y, Ono T, Fukuda K, Satoh T, Sasayama S. Evaluation of a new 
formulation of epoprostenol sodium in Japanese patients with pulmonary arterial 
hypertension (EPITOME4). Adv Ther. 2013 May;30(5):459-71. doi: 

Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Friendly link:

Copyright Copyright (C) 2018-2021 Taizhou Crene Biotechnology Co.,Ltd.  

Address:Economic Developed Zone of Taizhou Zhejiang China